tirzepatide and parkinson's disease GLP-1 does not slow progression in phase 3 study Frontiers | Neuroprotective effects of

Buyer pays for return postage

J Cell Physiol 232:6977

Given that calcimimetics, which activate the CaSR are already FDA approved and used in patients, these existing agents might be repurposed or redesigned as anti-obesity drugs

Tirzepatide, as the first GLP-1/GIP dual receptor agonist, demonstrated greater benefits in blood glucose control and weight reduction compared with GLP-1 single receptor agonists like semaglutide and dulaglutide, induced by the combined activation of both receptors.23,26 The latest results from the SURMOUNT-5 trial, published in May 2025, indicate that in obese individuals without diabetes, tirzepatide led to greater reductions in both weight and waist circumference compared with semaglutide